Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders
23 Mayo 2024 - 12:00AM
UK Regulatory
Idorsia issues invitation to the 2024 Annual General Meeting of
Shareholders
Allschwil, Switzerland – May 23, 2024
Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming
Annual General Meeting (AGM) of Shareholders on behalf of the Board
of Directors. The meeting to approve the Annual Report of the year
ending December 31, 2023, will be held on Thursday, June 13, 2024,
at 09.00 CEST at the Congress Center, Messe Basel, Switzerland.
Notes to Shareholders
The invitation was published in the Swiss Official Gazette of
Commerce (Schweizerisches Handelsamtsblatt) today and will be
distributed to Shareholders by post. It is also available, together
with the company’s Annual Report, consisting of the Business
Report, Governance Report, Compensation Report, Financial Report,
and for the first time, Sustainability Report, at
www.idorsia.com/agm.
In order to attend and vote at the AGM, shareholders must be
registered in the company's shareholder register by June 4, 2024,
17:00 CEST, at the latest.
Notes to the editor
Agenda for the AGM 2024
1. Annual reporting 2023
1.1 Vote on Annual Report 2023,
Consolidated Financial Statements 2023,
and Statutory Financial Statements 2023
1.2 Consultative vote on the
Compensation Report 2023
1.3 Consultative vote on the
Sustainability Report 2023
2. Appropriation of available earnings
3. Discharge of the Board of Directors and of the
Executive Committee
4. Amendments to the Articles of Association
regarding share capital
4.1 Increase of conditional
share capital
4.2 Deletion of Article 3C
5. Board elections
5.1 (Re-)election of members of
the Board of Directors
5.2 Election of the Chair of the
Board of Directors
5.3 Re-election of members of
the Nominating, Governance & Compensation Committee
6. Vote on Board compensation and Executive
Committee compensation
6.1 Approval of Board
compensation (Non-Executive Directors) for the
2024–2025 term of office
6.2 Approval of Executive
Committee compensation for 2025
7. Re-election of the Independent Proxy
8. Election of the statutory auditors
About Idorsia
Idorsia Ltd is reaching out for more – We have more ideas, we see
more opportunities and we want to help more patients. In order to
achieve this, we will develop Idorsia into a leading
biopharmaceutical company, with a strong scientific core.
Headquartered near Basel, Switzerland – a European biotech-hub –
Idorsia is specialized in the discovery, development and
commercialization of small molecules to transform the horizon of
therapeutic options. Idorsia has a 25-year heritage of drug
discovery, a broad portfolio of innovative drugs in the pipeline,
an experienced team of professionals covering all disciplines from
bench to bedside, and commercial operations in Europe and North
America – the ideal constellation for bringing innovative medicines
to patients.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol:
IDIA) in June 2017 and has over 750 highly qualified specialists
dedicated to realizing our ambitious targets.
For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate
Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123
Allschwil
+41 58 844 10 10
investor.relations@idorsia.com
media.relations@idorsia.com
www.idorsia.com
The above information contains certain "forward-looking
statements", relating to the company's business, which can be
identified by the use of forward-looking terminology such as
"estimates", "believes", "expects", "may", "are expected to",
"will", "will continue", "should", "would be", "seeks", "pending"
or "anticipates" or similar expressions, or by discussions of
strategy, plans or intentions. Such statements include descriptions
of the company's investment and research and development programs
and anticipated expenditures in connection therewith, descriptions
of new products expected to be introduced by the company and
anticipated customer demand for such products and products in the
company's existing portfolio. Such statements reflect the current
views of the company with respect to future events and are subject
to certain risks, uncertainties and assumptions. Many factors could
cause the actual results, performance or achievements of the
company to be materially different from any future results,
performances or achievements that may be expressed or implied by
such forward-looking statements. Should one or more of these risks
or uncertainties materialize, or should underlying assumptions
prove incorrect, actual results may vary materially from those
described herein as anticipated, believed, estimated or
expected.
Idorsia (LSE:0RQE)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Idorsia (LSE:0RQE)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
